

primary process of podocytes and its expression significantly decreases in idiopathic FSGS.
43rd American Society of Nephrology Renal Week, November 19, 2010, Denver, USA.

表1

カンデサルタンレキシチル(ブロプレス®)によるACEI/ARB fetopathy発症数

西暦	2004	2005	2006	2007	2008	2009	2010
ACEI/ARB fetopathy 患者数	1	2	1	2	2	0	1

表2

ディオバン(バルサルタン[®])によるACEI/ARB fetopathy発症数

西暦	2004	2005	2006	2007	2008	2009	2010
ACEI/ARB fetopathy 患者数	2	0	9	0	2	3	1

III 參考資料

腎性尿崩症に関するアンケート調査票

御所属 _____ 病院 _____ 科

御住所 〒 _____

御芳名 _____

質問 1. 過去に先生御自身あるいは貴診療科において、腎性尿崩症と診断された症例をご経験されていますか。いずれかに○をしてください。

ある ・ ない

質問 2. 質問 1.であるとお答えいただいた場合、症例数をお知らせ下さい。
(死亡された方も含みます。)

(_____ 人)

質問 3. 直接診療を担当されていない場合でも、腎性尿崩症の患者さまをご存知の場合は、医療機関、問い合わせさせていただく担当の先生等を可能な範囲でお教え下さい。

(医療機関： _____)

(担当医師： _____ 先生)

(医療機関： _____)

(担当医師： _____ 先生)

ご協力誠にありがとうございました。

腎性尿崩症に関するアンケート調査：2次調査票

経験された症例毎にお願いします。

該当する項目の□に印を、また記入欄も分かる範囲で結構ですので、よろしく
お願いいたします。

医療機関・診療科名	
連絡先医師のお名前	
email address	

同一の症例を複数の先生方でご登録されている場合は、本アンケートは一部に
まとめていただいて結構です。なお、症例の重複を避けるため、担当された先生方
のご芳名を下にご記入願えますでしょうか。

担当医師名	
-------	--

I. 患者背景

・患者情報

性別	<input type="checkbox"/> 男 <input type="checkbox"/> 女	
生年月日	<input type="checkbox"/> 昭和 <input type="checkbox"/> 平成	_____年（西暦_____）、_____月
発症推定年齢	_____歳_____ヶ月	
診断年齢	_____歳_____ヶ月	
基礎疾患	<input type="checkbox"/> あり <input type="checkbox"/> なし <input type="checkbox"/> 不明	
コメント (基礎疾患、薬剤等)		

・母体妊娠中の服用歴

ACEi：アンギオテンシン変換酵素阻害薬)	<input type="checkbox"/> あり	<input type="checkbox"/> なし	<input type="checkbox"/> 不明
ARB：アンギオテンシンⅡ受容体拮抗薬	<input type="checkbox"/> あり	<input type="checkbox"/> なし	<input type="checkbox"/> 不明
その他・コメント			

・家族歴（本症と関連があると思われるもののみで結構です）

尿崩症	<input type="checkbox"/> あり	<input type="checkbox"/> なし	<input type="checkbox"/> 不明
その他	<input type="checkbox"/> あり	<input type="checkbox"/> なし	<input type="checkbox"/> 不明
コメント			

Ⅱ. 発症時（初診時）の症状

<input type="checkbox"/> 口渇	<input type="checkbox"/> 多飲	<input type="checkbox"/> 多尿	<input type="checkbox"/> 夜尿
<input type="checkbox"/> 嘔吐	<input type="checkbox"/> 便秘	<input type="checkbox"/> 発熱	<input type="checkbox"/> 尿路感染症
<input type="checkbox"/> 痙攣	<input type="checkbox"/> 意識障害	<input type="checkbox"/> 体重増加不良	<input type="checkbox"/> 成長障害
<input type="checkbox"/> 精神発達遅滞			
<input type="checkbox"/> その他・コメント			

Ⅲ. 診断検査方法

<input type="checkbox"/> 水制限試験			
<input type="checkbox"/> 5%高張食塩水負荷試験			
<input type="checkbox"/> デスマプレシン（DDAVP）負荷試験			
<input type="checkbox"/> 尿浸透圧 _____ mOsm/kg			
<input type="checkbox"/> 血漿浸透圧 _____ mOsm/kg			
<input type="checkbox"/> 血清 Na 値（最高値） _____ mEq/l			
<input type="checkbox"/> 血漿 AVP 値（最高値） _____ pg/ml			
<input type="checkbox"/> 頭部 MR 下垂体後葉 T1 強調像高信号消失	<input type="checkbox"/> あり	<input type="checkbox"/> なし	
<input type="checkbox"/> その他・コメント			

IV. 遺伝子検査

<input type="checkbox"/> 実施 <input type="checkbox"/> 未実施	
遺伝子診断結果	

V. 診断

<input type="checkbox"/> 腎性尿崩症	<input type="checkbox"/> 先天性	
	<input type="checkbox"/> 二次性	<input type="checkbox"/> リチウム <input type="checkbox"/> その他
<input type="checkbox"/> 中枢性尿崩症		
<input type="checkbox"/> 心因性多尿		
<input type="checkbox"/> その他・分類不能		

VI. 治療（現在までに行った治療とその効果について）

<input type="checkbox"/> DDAVP（デスマプレシン）	反応性： <input type="checkbox"/> あり <input type="checkbox"/> なし
<input type="checkbox"/> サイアザイド系利尿薬	反応性： <input type="checkbox"/> あり <input type="checkbox"/> なし
<input type="checkbox"/> プロスタグランジン合成阻害薬 （インドメタシン等）	反応性： <input type="checkbox"/> あり <input type="checkbox"/> なし
<input type="checkbox"/> 非ステロイド性消炎鎮痛剤 （メフェナム酸：ポンタール等）	反応性： <input type="checkbox"/> あり <input type="checkbox"/> なし
<input type="checkbox"/> 塩分制限	反応性： <input type="checkbox"/> あり <input type="checkbox"/> なし
<input type="checkbox"/> その他・コメント	

VII. 治療副作用

<input type="checkbox"/> 頭痛	<input type="checkbox"/> 悪心・嘔吐	<input type="checkbox"/> 低 Na 血症	<input type="checkbox"/> 低 K 血症
<input type="checkbox"/> 成長障害	<input type="checkbox"/> 水中毒	<input type="checkbox"/> 急性腎不全	
<input type="checkbox"/> その他・コメント			

Ⅷ. 合併症

腎合併症	<input type="checkbox"/> 水腎症 <input type="checkbox"/> 水尿管 <input type="checkbox"/> 膀胱尿管逆流 <input type="checkbox"/> 腎不全 <input type="checkbox"/> アシドーシス
	<input type="checkbox"/> その他
<input type="checkbox"/> 精神発達遅滞：(<input type="checkbox"/> 軽度 <input type="checkbox"/> 重度 <input type="checkbox"/> 不明) <input type="checkbox"/> 痙攣（てんかん） <input type="checkbox"/> 脳梗塞・脳出血 <input type="checkbox"/> 血栓症	
<input type="checkbox"/> その他・コメント	

Ⅸ. 死亡の有無

<input type="checkbox"/> あり <input type="checkbox"/> なし	
死因 もしくは 現在の状況	

Ⅹ. 遺伝子解析について

患者様のご同意をいただけるようでしたら、当方で遺伝子解析の症例を募っております。

ご協力、誠にありがとうございました。

IV 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
神崎 晋	第10章内分泌疾患 C.甲状腺疾患	編集森川昭廣編集 内山 聖・原 寿 郎・高橋孝雄	標準小児科 学第7版	医学書院	東京	2010	232-236
神崎 晋	第11章内分泌疾患 H.糖尿病代謝異常	編集森川昭廣編集 内山 聖・原	標準小児科 学第7版	医学書院	東京	2010	259-264
神崎 晋	23.小児疾患 先天性 甲状腺機能低下症(ク レチン症)	総編集山口 徹,北 原光夫, 福井次矢	今日の治療 指針 TODA Y'S THER APY 2011	医学書院	東京	2011	1207- 1208
神崎 晋	第1章 成長・発達 A 身体発育	編集児玉浩子, 玉 井 浩, 清水俊明	小児臨床栄 養学	診断と治 療社	東京	2011	2-5
Igarashi T	Fanconi syndrome	Avner ED, Harmon WE, Niaudet P, Yoshikawa N	Pediatric Nep hrology six edition, vol 1	Springer- Verlag	Berlin	2009	1039- 1068
五十嵐隆	小児腎疾患の臨床	五十嵐隆	小児腎疾患の 臨床 改訂第 4版	診断と治 療社	東京	2010	1-332
五十嵐隆	Dent病患者の初めて の記載者	槇野博史編著	第53回日本腎 臓病学会学術 総会記念誌	日本腎臓 学会	東京	2010	46-47

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okuno K, Takashima K, Kanai K, Ohashi M, Hyuga R, Sugihara H, Kuwamoto S, Kato M, Sano H, Sairenji T, Kanzaki S, Hayashi K	Epstein-Barr Virus Can Infect Rabbits by the Intranasal or Peroral Route: An Animal Model for Natural Primary EBV Infection in Humans	J Med Virol	82	977-986	2010
Okada S, Saito M, Kinoshia Y, Satoh I, Kawaba Y, Hayashi A, Oite T, Sato K, Kanzaki S	Effects of cyclohexenonic long-chain fattyalcohol in type2 diabetic rat nephropathy	Biomed Res	31	219-230	2010
Iitsuka T, Murakami J, Nagata I, Kanzaki S, Shiraki K.	Epidemiological survey of Japanese children infected with hepatitis B and C viruses.	Hepatol Res	40	878-886	2010
神崎 晋, 宮原直樹, 西村 玲	フローチャートでみる私の処方 IV.内分泌疾患の処方 思春期早発症・遅発症	小児科臨床	63	845-851	2010
田中敏章, 伊藤純子, 神崎晋, 島津章, 田中弘之, 寺本明, 永井敏郎, 長谷川奉延, 羽二生邦彦, 藤田敬之助, 堀川玲子, 向井徳男, 和田尚弘, 横谷進	成長ホルモン分泌不全性低身長症における成長ホルモンによる前思春期の治療開始年齢別治療効果	日本成長学会雑誌	16	23-29	2010
遠藤有里, 櫻井由美, 木村真司, 石原千絵子, 鈴木康江, 南前恵子, 長石純一, 神崎晋, 花木啓一	胎児期・新生児期の体重増加量と周産期指標の関連	小児保健研究	69	373-379	2010
橋田祐一郎, 上山潤一, 佐野仁志, 奥野啓介, 呉 彰, 辻 靖弘, 西川健一, 神崎 晋	非血縁者間臍帯血移植で救命しえた治療抵抗性ランゲルハンス細胞組織球症の乳児例	日本小児血液学会雑誌	24	144-149	2010
花木啓一, 宮原直樹, 西村 玲, 鞆嶋有紀, 長石純一, 神崎 晋	【最新 成長障害の診かたと対応】奇形症候群と低身長 Prader-Willi症候群と Noonan症候群を中心に	小児内科	42	587-591	2010
鈴木康江, 前田隆子, 遠藤有里, 藤田小矢香, 池田智子, 南前恵子, 西村正子, 木村真司, 花木啓一	出生時体重が母親の育児に及ぼす影響 0~12歳児を持つ保護者への調査	米子医学雑誌	61	93-99	2010
花木啓一, 西村直子, 遠藤有里, 南前恵子, 田中敏章, 堀川玲子, 有阪治, 神崎晋	低身長児の心理的側面 新しい対面式身長イメージ評価尺度の開発	成長科学協会研究年報	33	35-45	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Luan Z, Higaki K, Aguilar-Moncayo M, Li L, Ninomiya H, Nanba E, Ohno K, García-Moreno MI, Ortiz Mellet C, García Fernández JM, Suzuki Y.	A fluorescent sp2-aminosugar with pharmacological chaperone activity for gaucher disease: synthesis and intracellular distribution studies.	Chembio-chem	11	2453-2464	2010
Li L, Higaki K, Ninomiya H, Luan Z, Iida M, Ogawa S, Suzuki Y, Ohno K, Nanba E.	Chemical chaperone therapy: Luciferase assay for screening of β -galactosidase mutations.	Mol Genet Metab.	101	364-369	2010
Morita T, Ashida A, Fujieda A, Hayashi A, Meda A, Ohta K, Shimizu M, Sekine T, Igarashi T, Tamai H, Wakiguchi H	Four cases of postrenal renal failure induced by renal stone associated with rotavirus infection.	Clin Nephrol	73	398-402	2010
Mizuno Y, Tsuchida S, Kakiuchi S, Ishiguro A, Goishi K, Kamei Y, Kanamori Y, Yamazaki Y, Sekine T, Igarashi T	Case report: Prenatal intervention for severe anterior urethral valve.	Pediatr Inter	52	e92-e95	2010
Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H, Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K, Miura K, Harita Y, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S	Patients with Epstein-Fechtner syndrome owing to <i>MYH9</i> R702 mutations develop progressive proteinuric renal disease.	Kidney Int	78	207-214	2010
五十嵐隆	ACEI/ARB fetopathy	腎と透析	68	1043-1045	2010
五十嵐隆	Hospital acquired hyponatremia	腎と透析	69	11-12	2010
五十嵐隆	腎疾患と電解質異常をきたす疾患の遺伝子学	最新医学	65	2069-2080	2010
五十嵐隆	尿細管機能評価法	腎臓	33	91-97	2010

V 研究成果の刊行物・別刷

42 Fanconi Syndrome

Takashi Igarashi

Fanconi syndrome (FS) is a generalized dysfunction of the renal proximal tubules leading to excessive urinary wasting of amino acids, glucose, phosphate, uric acid, bicarbonate, and other solutes. The patients develop failure to thrive, polyuria, polydipsia, dehydration, and rickets in children, and osteoporosis and osteomalacia in adults. The patients also manifest renal salt wasting, hypokalemia, metabolic acidosis, hypercalciuria, and low-molecular-weight (LMW) proteinuria. De Toni, Debré, and Fanconi described children with renal rickets and glucosuria in the 1930s (1, 2, 3). FS is named after Guido Fanconi, a Swiss pediatrician or it is called as de Toni-Debré-Fanconi syndrome.

Pathophysiology


The renal proximal tubules reabsorb almost all of the physiologically filtered load of proteins including of albumin, LMW proteins, amino acids, glucose, bicarbonate, sodium, chloride, phosphate, and uric acid. The transport processes in the proximal tubule can be characterized broadly as megalin/cubilin-mediated endocytic pathways and sodium (Na^+) gradient-dependent transport systems.

The proximal tubule cells have extensive luminal receptors and endocytic apparatus such as megalin and cubilin that are critical for the reabsorption and degradation of proteins that traverse the glomerular filtration barrier (4) (Fig. 42-1) as well as for the extensive recycling of many functionally important membrane proteins (5). Numerous filtered proteins including albumin, LMW proteins, polypeptide hormones, vitamin-binding proteins, and polybasic drugs such as aminoglycosides from glomerulus are bound to megalin and cubilin in the luminal membrane of proximal tubules. Then, the protein-receptor complex is incorporated into the endosome. The ligand and receptor are disassociated in the endosome; the receptor is recycled back to the luminal membrane and the reabsorbed proteins go into lysosome for further processing (Fig. 42-2). This disassociation is dependent on acidification of the endosome by increased concentration of H^+ and Cl^- due to the function of H^+ -ATPase (proton pump) and ClC-5 chloride channel. An abnormal

endocytosis pathway may affect the recycling of transport proteins (megalin and cubilin), the back to the luminal membrane, and the expression of megalin and cubilin in the luminal membrane, leading to decreased solute reabsorption. Perturbation of endosomal acidification in proximal tubule cells leads to diminished reabsorption and increased urinary wasting of albumin, LMW proteins, electrolytes, and solutes. Cadmium inhibits H^+ -ATPase and mitochondria, which results in a Fanconi-like syndrome (6). Folic acid, a H^+ -ATPase inhibitor, abolishes albumin uptake by proximal tubules (7). Moreover, a defect of ClC-5 chloride channel in patients with Dent disease manifests Fanconi syndrome (8). Acidification defect in the endosome in Dent disease leads to recycling from intracellular endosome into luminal membrane resulting in megalin deficiency in the luminal membrane of the proximal tubule. Analysis of normal human urine samples identified megalin as a physiologically excreted protein. The presence of megalin in normal human urine is due to shedding from the proximal tubule cells into the lumen. Patients with Dent disease demonstrate an almost complete absence of urinary megalin (9). This megalin-shedding deficiency in the urine is also observed in patients with Lowe syndrome (9).

Reabsorption of filtered solutes including glucose, phosphate, amino acids, and bicarbonate by proximal tubule cells is accomplished by transport system at the brush border membrane that are directly or indirectly coupled to Na^+ movement, by energy production and transport from the mitochondria, and by the Na^+ , K^+ -ATPase at the basolateral membrane. The Na^+ , K^+ -ATPase lowers intracellular Na^+ concentration and provides the electrochemical gradient that allows Na^+ -coupled solute entry into the cell. Disturbances in energy generation could impair net transepithelial transport in the proximal tubule. Energy is necessary for the operation of Na^+ , K^+ -ATPase and other membrane carriers that are involved with solute reabsorption of amino acid, glucose, phosphate, uric acid, and bicarbonate. Although the weight of bilateral kidneys is less than 1% of total body weight, kidneys consume about 10% of the total energy consumed by the whole body in a static condition. Moreover, most of the energy is consumed in the proximal tubule cells to operate multiple

megalin and cubilin. (Veroust PJ, Bim H, Nielsen R et al. The tandem endocytic receptors megalin and cubilin proteins in renal pathology. *Kidney Int* 2002;62:745-756).




and intracellular transporter proteins. A defect in the proximal tubule cells produces transport anomalies of the proximal tubule that are characteristic of Fanconi Syndrome (FS). The ATP production is severely compromised in the proximal tubule in cystinosis (10). Transporting enzymes are critical for renal energy metabolism. Cystine inhibits in vivo and in vitro the activity of several enzymes resulting in multiple transport anomalies (11). The mitochondrial

respiratory chain has a major role in ATP production during aerobic respiration. Genetic defects of enzyme complexes of the oxidative phosphorylation system or toxic substances including of drugs in the proximal tubule cells can produce mitochondrial respiratory chain defect leading to multiple renal transport anomalies (12, 13). In contrast, isolated dysfunction of transporter proteins in proximal tubule cells results in the selective wasting of amino acids, glucose, phosphate, bicarbonate, or uric

Figure 42-2

Schematic model of endocytosis in the proximal tubule cells. Albumin and low molecular weight proteins are filtered in the primary urine and endocytosed by proximal tubule cells via the megalin-cubilin receptor pathway. (a) The receptor ligand complexes progress along the endocytic pathway. The endosomes undergo a progressive, ATP-dependent acidification that results in the dissociation of the receptor-ligand complexes, with megalin and cubilin being recycled to the luminal membrane, whereas the ligand is directed to lysosomes for degradation. (b) Vesicular acidification is mediated by the vacuolar H^+ -ATPase, which requires a net Cl^- conductance to function as an electrogenic nCl^-/H^+ exchanger, which is predicted to facilitate acidification and to play a role in keeping high vesicular Cl^- concentration. (Devuyst O, Pirson Genetics of hypercalciuric stone forming disease. *Kidney Int* 2007;72:1065-1092).



acids. However, glucosuria and aminoaciduria are seen in some patients with defective isolated proteins. They are familial renal glucosuria resulting from the mutations in the kidney-specific low affinity/high capacity Na^+ /glucose cotransporter gene (*SLC5A2*) and maturity-onset diabetes of young age type 3 (*MODY3*) resulting from the mutations in hepatocyte nuclear factor-1 alpha gene that acts as a regulator of transcription for *SLC5A2* (14, 15). Generalized aminoaciduria seen in these patients is considered as a consequence of the impairment in tubular glucose reabsorption, whereas the precise mechanism is not known.

Signs and Symptoms

Growth Retardation (Failure to Thrive)

Growth retardation (failure to thrive) is a common feature of FS in children (16). Patients with FS present severe

growth failure at the time of diagnosis that persists in adult life. The pathomechanism of growth failure in FS complex. Malnutrition, hypokalemia, hypophosphatemia and metabolic acidosis can lead to growth retardation in patients with FS (17). Potassium deficiency induces growth retardation through reduced circulating levels of growth hormone (GH) and insulin-like growth factor (IGF-I) (18, 19). Hypokalemia can induce appetite decrease leading to malnutrition and extracellular volume contraction. Metabolic acidosis inhibits growth hormone secretion, the expression of IGF-I and GH receptor (20). Hypophosphatemia is related to severe bone changes leading to rickets and growth retardation in children with FS (21). In patients with adult onset FS, osteomalacia is thought to result from hypophosphatemia due to renal phosphate loss and relative 1,25-dihydroxyvitamin D deficiency (22, 23). Metabolic acidosis impairs the conversion of 25-vitamin D₃ to 1,25-dihydroxyvitamin D₃. The patients present bone and joint pain in the hip

and trunk and difficulty of walking due to the fracture. Hypomineralization of dentin and immature formation of craniofacial bones in patients with FS (24). Specific forms of FS are associated with endocytosis pathway dysfunction; disintegrin-mediated uptake vitamin D-binding protein complex produces metabolic bone defects in affected individuals (25).

Prognosis and efficient correction of acidosis and rickets by supportive therapy can contribute to growth and final height in patients with FS. However, supportive therapy is frequently unable to prevent further loss of relative height in patients with FS, as in those with cystinosis.

Polydipsia, and Dehydration

Polydipsia, and dehydration are frequently seen in patients with FS. Polyuria is secondary to the osmotic effect of the excessive urinary solute losses and urine concentration defect in the collecting ducts due to chronic renal tubular acidosis. Recurrent acute fever due to dehydration is a common manifestation in infants with FS. In the most severe form of cystinosis, Fanconi syndrome occurs at an early age. Recurrent febrile episodes are often associated with FS in infantile patients with cystinosis (26).

Generalized Aminoaciduria (Generalized Aminoaciduria)

The molecular weight (MW) of 20 different amino acids is less than that of the most abundant amino acid is tryptophan [MW = 204 D]. Most amino acids are not bound to proteins in the plasma and are freely filtered from glomerular capillaries. 99% of filtered load of amino acids are reabsorbed in the proximal tubules. More than one transporter in proximal tubule cells absorbs amino acids. The fractional reabsorption of amino acid is usually less than 3% except for neonate or premature babies. Histidine has a fractional excretion of 5%.

$$\text{Fractional excretion of amino acid (\%)} = \frac{U_a/P_{aa}}{(U_{cr}/P_{cr})} \times 100$$

U, cr; creatinine, U; urine, P; plasma)

The fractional excretion more than 5% of the filtered load of an amino acid is termed aminoaciduria or hyperaminoaciduria. Every amino acid is highly excreted in

patients with FS, and this phenomenon is called as *generalized aminoaciduria*.

Glucosuria

Filtered load of glucose (D-glucose, MW = 180 D) is almost completely absorbed by a sodium-coupled active transport located in the brush border membrane of the proximal tubule in the normal condition. Glucose reabsorption involves a couple of transporters at the luminal and basolateral membranes of the proximal tubules. The driving force for glucose reabsorption is provided by Na⁺, K⁺-ATPase in the plasma membrane. Thus, very small amount of glucose are present in the urine in the normal condition. Glucosuria is a common manifestation in FS. It is derived from impaired reabsorption of glucose when serum glucose is normal. Renal threshold of glucose is reduced in FS. Glucosuria is one of the originally described clinical features of FS (1, 2, 3). 0.5–20 g of glucose a day is lost in the urine in patients with FS.

Hypophosphatemia

Most of the patients with FS manifest a low tubular reabsorption of phosphate (percent tubular reabsorption of phosphate: %TRP, >80–85% in the control) and decreased serum phosphate. Rickets and osteomalacia are produced by the increased urinary wasting of phosphate as well as by impaired 1 α -hydroxylation of 25-hydroxy vitamin D₃ by proximal tubule cells (27).

$$\%TRP = [1 - (U_p/S_p)/(U_{cr}/S_{cr})] \times 100$$

(p; phosphate, cr; creatinine, U; urine, S; serum)

The maximal threshold of phosphate (T_mP/GFR) is a very sensitive indicator that reflects the reabsorption of phosphate in the renal tubules.

$$T_mP/GFR = TRP \times Sp$$

(GFR; glomerular filtration rate, p; phosphate, S; serum)

The T_mP/GFR is usually very low (2.3–4.3 in the control) in patients with FS. Rickets manifests bowing deformity of the lower limbs, distal femur, the ulna, and the radius.

Phosphate handling in the kidney is affected by a couple of factors including parathyroid hormone (PTH) and vitamin D. PTH level is normal or elevated in patients with FS. Serum 1, 25-dihydroxy vitamin D₃ is variable in patients with FS (28, 29).

Metabolic Acidosis

More than 85% of filtered load of bicarbonate (HCO_3^-) is reabsorbed by the proximal tubule cells. This is accomplished by the coordinated function of luminal membrane Na^+/H^+ exchanger, luminal membrane carbonic anhydrase IV and XIV, and basolateral membrane $\text{Na}^+/\text{HCO}_3^-$ cotransporter (30). Hyperchloremic metabolic acidosis is a common feature of FS resulting from defective bicarbonate reabsorption in the proximal tubules. Anion gap is normal. More than 30% of filtered load of HCO_3^- is not reabsorbed in patients with FS, and they manifest low plasma HCO_3^- levels between 12–18 mEq L^{-1} . Fractional excretion of HCO_3^- (FEHCO_3^-) under the alkali treatment to increase plasma HCO_3^- to the normal ranges is >15% in patients with FS.

$$\text{Fractional excretion of } \text{HCO}_3^- \% = \frac{[(\text{UHCO}_3^- / \text{PHCO}_3^-) / (\text{Ucr/Pcr})] \times 100}{(\text{HCO}_3^-; \text{bicarbonate, cr; creatinine, U; urine, P; plasma})}$$

Acidification in the distal tubule is usually normal or impaired in association with chronic hypokalemia or toxic effect on distal tubules due to the original disorder in patients with FS.

Sodium and Potassium Losses

60–80% of filtered load of Na^+ is reabsorbed in the proximal tubules in the normal condition. Renal Na^+ reabsorption in the proximal tubules decreased in patients with FS. It leads to hyponatremia, hypotension, and dehydration. Hypokalemia is a secondary phenomenon. Increased delivery of Na^+ into the distal tubules and activation of the renin-angiotensin system secondary to hypovolemia cause potassium (K^+) wasting in the distal tubules. Severe hypokalemia can cause sudden death.

Hypercalciuria

Hypercalciuria is a common finding in patients with FS due to several original diseases. Defective endocytosis of parathyroid hormone (PTH) in patients with Dent disease resulting in its persistence in the lumen of the proximal tubule stimulates 25-hydroxyvitamin D3 1-hydroxylase to produce more 1,25-dihydroxyvitamin D3, raising serum levels of this vitamin. 25-hydroxyvitamin D3 is presented to 25-hydroxyvitamin D3 1-hydroxylase in the form of a

complex with the vitamin D3-binding protein. As this complex is lost in the urine as a result of defective endocytosis leading to LMW proteinuria, the precursor 25-hydroxyvitamin D3 could be in short supply. The overall outcome of increased 1, 25-dihydroxyvitamin D3 levels may depend on the delicate balance between these processes. The slightly elevated serum levels of 1, 25-dihydroxyvitamin D3 in patients with FS can lead to increased intestinal Ca^{2+} reabsorption which will lead to hypercalciuria (*absorptive hypercalciuria*) (29). Hypercalciuria is rarely associated with nephrolithiasis in FS, possibly because of the polyuria and alkalinized urine. However, patients with Dent disease manifest hypercalciuria and nephrolithiasis.

Hyperuricosuria (Uricosuria)

Uric acid (urate) is the end product of purine metabolism in humans. Because of its small molecular size (MW = 126 D), uric acid is freely filtered from the glomerulus. Then, 90–95% of filtered load of uric acid is eventually reabsorbed in the proximal tubules. A four-component hypothesis has been proposed to explain the renal uric acid transport mechanism; it includes glomerular filtration, presecretory reabsorption, secretion, and postsecretory reabsorption (31). Hyperuricosuria is often present in FS, leading to secondary hypouricemia (<2 mg dL^{-1}) (32). A voltage-sensitive uric acid pathway and uric acid exchangers are located at both luminal and basolateral membranes of proximal tubule cells (33). Uric acid-anion exchanger (URAT1) that reabsorbs uric acid from the lumen of the proximal tubules in the luminal membrane of proximal tubules regulates serum uric acid levels. This uric acid-anion exchanger can be disturbed in patients with FS. Defective URAT1 is a predominant cause of the patients with renal hypouricemia who manifest acute renal failure after exercise (34, 35). Hexose transporter gene (*SLC2A9*) is identified as a cause of gout and hyperuricemia (36). This transporter transports both fructose and uric acid. *SLC2A9* produces two isoforms by alternative splicing; the long isoform is expressed in basolateral membrane of proximal tubular cells and the short isoform is expressed in apical membrane of proximal tubular cells. This hexose transporter can be affected in patients with FS. Uric acid is a selective antioxidant, capable especially of reaction with hydroxyl radicals and hypochlorous acid, itself being converted to innocuous products such as allantoin, allantoate, glyoxylate, urea, and oxalate (37).

a (LMW Proteinuria)

Proximal tubules have a high capacity for uptake of proteins from the glomerulus. The cut off molecular weight for filtration of plasma proteins is assumed to be that of 65 KD (kilodaltons) that corresponds to the molecular weight of serum albumin. However, small molecular weight proteins including gammaglobulin are filtered from glomerulus in the normal condition and LMW proteins (MW < 45,000 D) are filtered from glomerulus. Filtration of albumin and LMW proteins are followed by tubular reabsorption and thus the resulting albuminuria and proteinuria reflect the combined contribution of glomerular and tubular processes. Dysfunction of both these processes results in increased urinary excretion of albumin and proteinuria, and both glomerular injury and tubular dysfunction have been implicated in the initial events leading to proteinuria. In FS, proteinuria is predominantly due to the dysfunction of reabsorption in the proximal tubule. Adolescent patients with FS due to Dent disease excrete greatly increased amounts of proteins ($1,740 \pm 660$ mg/day) and peptide hormones (100 mg/day). LMW proteins ranging from 2 to 100 kD are present in 12.9 ± 3.9 -fold excess in FS compared to normal urine (38). The micropuncture studies revealed that the filtered load of albumin is 3.5 g m^{-2} suggesting that a filtered load of 1.5 g/day in normal humans (39). However, the reabsorption of protein is less than 0.1–0.15 g/day in normal condition. Numerous filtered proteins including albumin and LMW proteins from glomerulus are reabsorbed in the proximal tubules. Then, the protein-receptor complex is internalized into the endosome. The ligand and receptor are dissociated in the endosome; the receptor is recycled to the luminal membrane and the ligands go into lysosome for further processing. Cubilin is a 100 KD glycoprotein and a member of the transferrin receptor family. Megalin is a 100 KD protein in the proximal tubule brush-border and luminal membrane apparatus. Megalin binds to a number of different proteins. It contains a large extracellular domain, a single transmembrane domain and a short carboxy-terminal cytoplasmic domain (40). Cubilin is a multiligand, endocytic receptor (41, 42). It is expressed in the proximal tubule brush-border and endocytic apparatus. Megalin involved in

albumin reabsorption directly as a receptor for albumin, and/or indirectly by affecting the expression and/or endocytic function of cubilin (40, 41). Megalin's expression was decreased in patients with Dent disease. Acidification defect due to endosomal defective ClC-5 in patients with Dent disease disturbs the recycling from intracellular endosome into luminal membrane of the proximal tubule resulting in megalin and cubilin deficiency in the luminal membrane of the proximal tubule.

Etiologies

The causes of FS are divided into three main categories; hereditary, acquired, and exogenous substances (see Table 42-1). Most of the hereditary FS occurs as one of the manifestations of congenital metabolic disorders or as sporadic or familial disorders. Acquired forms are derived from immunological reactions, nephrotic syndrome or accumulated abnormal proteins. Exogenous substances are composed of drugs, chemical compounds, and heavy metals.

Hereditary Fanconi Syndrome

Dent Disease

Dent disease is an X-linked proximal tubulopathy characterized by LMW proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis, and eventual end stage renal failure. Hypophosphatemic rickets and metabolic acidosis are sometimes seen (42, 43). Almost all of the patients are males. Adult patients with Dent disease manifest FS. However, children with Dent disease often manifest LMW proteinuria and one or two of the manifestations due to proximal tubular dysfunction and this is called partial FS (44). They usually fall into end stage renal failure by the age of 40s. However, this is highly variable, and one third of patients with Dent disease will not develop end stage renal failure. Patients with Dent disease never manifest extrarenal manifestations, except for rickets, which may itself be a consequence of phosphaturia. School children with Dent disease manifest proteinuria. A lot of school children with Dent disease are detected as proteinuria by school urine mass screening program in Japan, and it was called as idiopathic low molecular weight proteinuria (45, 46). Carrier females are often manifest less severe LMW proteinuria and hypercalciuria, depending on X-chromosome inactivation, but they rarely develop clinically significant problems.